EG01377 2HCl

TargetMol
Product Code: TAR-T11154L
Supplier: TargetMol
CodeSizePrice
TAR-T11154L-1mg1mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-5mg5mg£378.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-1mL1 mL * 10 mM (in DMSO)£516.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-10mg10mg£527.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-25mg25mg£805.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-50mg50mg£1,075.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-100mg100mg£1,420.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11154L-500mg500mg£2,777.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 uM and an IC50 value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.EG01377 exhibits anti-angiogenic, antimigratory and antitumor activities.
CAS:
2749438-61-5
Formula:
C26H32Cl2N6O6S2
Molecular Weight:
659.6
Pathway:
Immunology/Inflammation
Purity:
0.9956
SMILES:
N=C(N)NCCC[C@@H](C(O)=O)NC(C(SC=C1)=C1NS(=O)(C2=C3C(CCO3)=CC(C4=CC=C(C=C4)CN)=C2)=O)=O.Cl.Cl
Target:
Complement System

References

Klaewkla M, et al. Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists. J Mol Liq. 2021;335:116537. Zhang P, et al. NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation. Cell Death Dis. 2023;14(2):159. Powell J, et al. Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGF?) Production in Regulatory T-Cells. J Med Chem. 2018;61(9):4135-4154.